key: cord-0758759-rzul1xf4
authors: Shapira, Tirosh; Monreal, I. Abrrey; Dion, Sébastien P.; Jager, Mason; Désilets, Antoine; Olmstead, Andrea D.; Vandal, Thierry; Buchholz, David W.; Imbiakha, Brian; Gao, Guang; Chin, Aaleigha; Rees, William D.; Steiner, Theodore; Nabi, Ivan Robert; Marsault, Eric; Sahler, Julie; August, Avery; Van de Walle, Gerlinde; Whittaker, Gary R.; Boudreault, Pierre-Luc; Aguilar, Hector C.; Leduc, Richard; Jean, François
title: A novel highly potent inhibitor of TMPRSS2-like proteases blocks SARS-CoV-2 variants of concern and is broadly protective against infection and mortality in mice
date: 2021-05-04
journal: bioRxiv
DOI: 10.1101/2021.05.03.442520
sha: db0dda6bab0996a4d6502c8bbe84e3a05ba71c4f
doc_id: 758759
cord_uid: rzul1xf4

The COVID-19 pandemic caused by the SARS-CoV-2 virus remains a global public health crisis. Although widespread vaccination campaigns are underway, their efficacy is reduced against emerging variants of concern (VOCs) 1,2. Development of host-directed therapeutics and prophylactics could limit such resistance and offer urgently needed protection against VOCs 3,4. Attractive pharmacological targets to impede viral entry include type-II transmembrane serine proteases (TTSPs), such as TMPRSS2, whose essential role in the virus lifecycle is responsible for the cleavage and priming of the viral spike protein 5–7. Here, we identify and characterize a small-molecule compound, N-0385, as the most potent inhibitor of TMPRSS2 reported to date. N-0385 exhibited low nanomolar potency and a selectivity index of >106 at inhibiting SARS-CoV-2 infection in human lung cells and in donor-derived colonoids 8. Importantly, N-0385 acted as a broad-spectrum coronavirus inhibitor of two SARS-CoV-2 VOCs, B.1.1.7 and B.1.351. Strikingly, single daily intranasal administration of N-0385 early in infection significantly improved weight loss and clinical outcomes, and yielded 100% survival in the severe K18-human ACE2 transgenic mouse model of SARS-CoV-2 disease. This demonstrates that TTSP-mediated proteolytic maturation of spike is critical for SARS-CoV-2 infection in vivo and suggests that N-0385 provides a novel effective early treatment option against COVID-19 and emerging SARS-CoV-2 VOCs.

The COVID-19 pandemic caused by the SARS-CoV-2 virus remains a global public health crisis. 24

Although widespread vaccination campaigns are underway, their efficacy is reduced against emerging 25 variants of concern (VOCs) 1,2 . Development of host-directed therapeutics and prophylactics could limit 26 such resistance and offer urgently needed protection against VOCs 3,4 . Attractive pharmacological targets 27

to impede viral entry include type-II transmembrane serine proteases (TTSPs), such as TMPRSS2, whose 28 essential role in the virus lifecycle is responsible for the cleavage and priming of the viral spike protein 5-29 7 . Here, we identify and characterize a small-molecule compound, N-0385, as the most potent inhibitor of 30 The peptidomimetics were tested for inhibitory activity against TMPRSS2 at 10 nM ( Figure 1B) . 119

Camostat mesylate (Cm), which has previously been shown to be active against TMPRSS2 32 , reduced 120 substrate proteolysis by 56% compared to untreated TMPRSS2-expressing cells. The first-generation 121 peptidomimetic, N-0100, did not inhibit TMPRSS2 activity under these conditions. However, the more 122 stable tetrapeptides with N-terminus desamino moieties, N-0130 and N-0438, had increased inhibitory 123 activity of 72% and 84%, respectively. N-0678 (substituting P2 Phe for the synthetic amino acid Cha) 124 only inhibited TMPRSS2 activity by 5%. N-0676 (a tripeptide with an N-terminal Ac cap and P2 Cha) 125 also weakly inhibited TMPRSS2 activity by 8%. N-0386 (restoring Phe in P2) resulted in more potent 126 inhibition of 73%. N-1296 (replacing Ac with Am) had reduced potency of 16%, while N-0385 (replacing 127

Am with Ms) resulted in a highly potent inhibition of 83%. Importantly, several peptidomimetic 128 compounds were more efficient than Cm at reducing TMPRSS2 activity ( Figure 1B) . 129 We then investigated the dose response of the four most promising peptidomimetics (N-0130, N-130 0385, N-0386, and N-0438). The half-maximal inhibitory concentration (IC 50 ) of Cm was 17.5 ± 18.8 nM, 131 while the IC 50 for N-0130 was 3.1 ± 1.5 nM; for N-0438 it was 5.2 ± 5.4 nM; for N-0386 it was 3.9 ± 4.4 132 nM; and for N-0385 it was 1.9 ± 1.4 nM ( Figure 1C and Table S1 ). Importantly, none of the compounds 133 affected Vero E6 cellular viability when used at 10 µM ( Figure S2 ). To confirm the contribution of the 134 ketobenzothiazole warhead to the molecule's inhibitory activity, the ketone functional group of N-0385 135 was replaced with an alcohol group to generate N-0385(OH) (Figure 1A) , which we predict no longer 136 traps the target protease. No significant reduction in TMPRSS2 activity was detected when cells were 137 treated with up to 10 µM of N-0385(OH) (Figure 1C) , suggesting that the integrity of the 138 ketobenzothiazole group is required to achieve potency. 139

Next, we sought to determine the selectivity profile of these inhibitors by measuring the 140 dissociation constant K i on selected recombinant serine proteases, including three members of the TTSP 141 family (matriptase, hepsin, DESC1) as well as furin, thrombin, and cathepsin L. All four peptidomimetic 142 compounds we tested behaved as low nanomolar inhibitors for the TTSPs, but they were inactive or 143

showed only weak inhibition against the other proteases ( Figure 1D and Table S2 ). Cm displayed a 144 similar selectivity profile to the peptidomimetics tested, except that it demonstrated moderate inhibition of thrombin (K i = 621 nM) in line with its broader spectrum properties. Overall, TTSP-targeting 146 peptidomimetics harbouring a ketobenzothiazole warhead inhibit TMPRSS2-dependent pericellular 147 activity in a cellular assay and preferentially inhibit other members of the TTSP family. 148

To understand the mode of binding and the main interactions of our inhibitors and how these 149 compounds achieve their high inhibitory potential, we built a homology model of TMPRSS2 using the 150 crystal structure of matriptase (PDB: 6N4T). Alignment of the catalytic domains demonstrated 41% and 151 60% identity and sequence similarity, respectively, making it a reliable model, especially near the 152 conserved binding site. Docking of N-0385 was modeled to this structure ( Figure 1E) . As predicted and 153 recently published 33 , the catalytic triad Ser441 (catalytic triad: Ser441, His296, and Asp345; Figure 1E 154 inlet) forms a covalent bond with the warhead ketone, thus leading to a tight-binding mode of inhibition. 155

Several key interactions can be observed in the binding pocket. As in all TTSP inhibitors 156 possessing a guanidine group on the side-chain, a strong hydrogen bond network stabilizes this 157 pharmacophore deep within the binding pocket ( Figure 1E ). This includes Asp435 and Gly464 as well as 158

Gln438 via a water molecule. Gln438 is also involved in another hydrogen bond of this same water 159 molecule to the inhibitor's glutamine ketone. This ketone also acts as a hydrogen bond acceptor with 160

Gly462. The N-terminal mesylate forms two hydrogen bonds, one intramolecular with the terminal amide 161 of N-0385 and another with Gly462. Finally, the oxygen of the newly formed hemiacetal is stabilized by 162 two hydrogen bond donors from the Gly439 and Ser441 amines. A portion of the ketobenzothiazole 163 warhead and the aromatic ring from the phenylalanine are exposed to the solvents, which could allow us 164 to further optimize the design of this second-generation inhibitor leading to an improved pharmacokinetic 165 profile. profiles across dsRNA and nucleocapsid staining, which mirrored the inhibitory profile observed in the 175 TMPRSS2 proteolytic activity assay (Figure 2A versus Figure 1B) . Cm, which interferes with SARS-176

CoV-2 infection 4 , reduced infection by >83% compared to non-treated cells. N-0100, which lacks an N-177 terminal stabilizing moiety, reduced infection by <25%. The tetrapeptides N-0130 and N-0438, which have N-terminus desamino moieties, had greatly increased antiviral activity of >93% and >88%, 179 respectively. N-0678 (substituting P2 Phe for the synthetic amino acid Cha) inhibited SARS-CoV-2 by 180 <23%. N-0676 (tripeptide with an N-terminal Ac cap and P2 Cha) had only moderate inhibitory activity 181 of <53%. N-0386 (restoring Phe in P2) resulted in a highly potent SARS-CoV-2 inhibition of >99%. N-182 1296 (replacing Ac with Am) reduced the antiviral potency to <44%, while N-0385 (capping with Ms) 183 Table  194 S1). Thus, the selectivity index (SI) for these compounds (N-0130, N-0438, N-0386, and N-0385) was 195 between 8.97 X10 4 and 2.75 X10 6 (Table S1). Overall, these results confirm that two newly discovered We first investigated the susceptibility of colonoid monolayers 37 to SARS-CoV-2 infection. Consistent 213 with previous work, the colonoids were susceptible to infection as evidenced by dsRNA and nucleocapsid 214 staining ( Figure 2D and Figure S4 ) 39, 40 . 

After establishing the efficacy of N-0385 in vitro and in cellulo, we tested whether intranasal 240 administration would be protective in vivo, using K18-hACE2 mice expressing the human ACE2 receptor 241 driven by a keratin promoter 41,42 , an established mouse model of severe SARS-CoV-2 disease 43 . K18-242 hACE2 mice express the human ACE2 receptor driven by a keratin promoter 41,42 . In the first experiment, 243 ten mice per group (five female and five male) were administered a single daily intranasal dose of 7.2 mg/kg N-0385, N-0385(OH), or a vehicle control (0.9% saline) for eight days from day -1 to day 6 245 relative to infection. The mice were challenged on day 0 with 1 x 10 3 PFU/mouse of SARS-CoV-2 246 ( Figure 4A ). Weight loss and survival data indicate that mice receiving N-0385 exhibited greatly reduced 247 morbidity and mortality compared to untreated mice ( Figure 4B-E) . N-0385-treated mice exhibited lower 248 weight loss (average 3%) and greater survival (70%) in stark contrast with N-0385(OH)-or saline-treated 249 mice, which had significantly greater weight loss (average ~14% for both) and poor survival (10% and 250 0%, respectively). 251

Histological examination of lung tissue revealed mild pathology in the majority of SARS-CoV-2 252 infected mice, with mild perivascular and interstitial inflammatory infiltrates as the predominant change, 253

irrespective of treatment group (Table S3) . Saline-treated mice frequently had additional histological 254 changes including alveolar edema, alveolar fibrin, and inflammatory cells within alveoli. Of the mice that 255 survived up to the study endpoint, three had focal areas of fibrosis, type II pneumocyte hyperplasia, and 256 occasionally lymphoid hyperplasia. However, the majority of the mice that survived showed little to no 257 pathological signs in the lungs ( Figure 4F ). Histologic lesions in the brain included multifocal 258 perivascular cuffs of inflammatory cells, reactive glial cells, neutrophils, and lymphocytes in the adjacent 259 neuroparenchyma (gliosis), infiltration of the meninges with inflammatory cells, and neuronal necrosis 260 characterized by shrunken neuron bodies with hypereosinophilic cytoplasm and pyknotic or karyorrhectic 261 nuclei. No lesions were observed in the brains of mice that survived to the study endpoint ( Figure 4G and 262 Table S3 ). 263

Immunohistochemistry of the SARS-CoV-2 nucleocapsid protein revealed significant amounts of 264 the viral antigen throughout the brain and lungs of infected mice treated with saline or N-0385(OH) 265 ( Figure 5 and Table S4 ). Antigen was detected in the brain, the lung, or both tissues for most of the 266 infected mice ( Figure 5 and Table S4 ). The amount of antigen detected in the brain and lung was reduced 267 significantly or completely absent in mice treated with N-0385 that survived to the study endpoint 268 ( Figure 5 and Table S4 ). 269

We then evaluated the outcome of a shortened regimen using ten mice per group treated with N-270 0385 or saline from day -1 to day 2 relative to infection ( Figure 6A ). The N-0385-treated mice in this 271 group showed 100% survival compared to 20% survivial in the control group, while the treated group had 272 an average 2% weight gain compared to average 14% weight loss in the control group (Figure 6B-D) . 273

Combined, all in vivo data strongly indicate that N-0385 significantly prevents morbidity and mortality in 274 the K18-hACE2 mouse model of severe SARS-CoV-2 disease, even when treatment was limited to early 275 infection. 276

In the present study, we report on N-0385, the most potent small-molecule protease inhibitor of 279 human TMPRSS2 and the first broad-spectrum nanomolar coronavirus HDA of SARS-CoV-2 VOCs. N- In this work, we present the design and use of small molecule peptidomimetics with 297 ketobenzothiazole warheads, which led to the identification of N-0385, a compound with potent 298 inhibitory activity against TMPRSS2 proteolytic activity (IC 50 = 1.9 nM). When we screened selected 299 TMPRSS2 inhibitors for antiviral activity against SARS-CoV-2, a similar inhibitory profile was observed 300 against TMPRSS2 expressed in Vero E6 cells compared to SARS-CoV-2 infection in Calu-3 cells. N-301 0385, the lead antiviral candidate, demonstrated potent inhibition of SARS-CoV-2 infection in Calu-3 302 cells, with an ED 50 of 2.8 ± 1.4 nM and a SI of > 1 x 10 6 . The potency of this compound was validated 303

using two viral biomarkers of intracellular infection as well as by measuring release of infectious viral 304 particles. Further, complete inhibition of infection was achieved with 100 nM N-0385 in colonoids 305 derived from human donors confirming the low nanomolar potency of N-0385 against SARS-CoV-2. To 306 date, GC-376, a DAA targeting 3CL pro , is the only other lead antiviral candidate for SARS-CoV-2 for 307 which a comparable SI to N-0385 has been reported in bioRxiv 48 . 308

The usefulness of N-0385 needs to be envisaged in the context of the currently circulating SARS-309 as well as their extensive spike mutations, which could lead to conformational changes of the trimeric 311 spike structure, which may be detrimental to antiviral effectiveness and vaccine protection 2,12,49 . We 312 speculate that N-385 inhibitory efficacy against these two SARS-CoV-2 VOCs should not be 313 compromised since no mutations in the TMPRSS2 cleavage site have been reported for these two SARS-314

CoV-2 VOCs 12 . Our results confirmed the broad-spectrum nanomolar antiviral activity of N-0385 against 315 SARS-CoV-2 B.1.1.7 and B.1.351 in human cells. 316

Recent studies have shown that the K18-hACE2 mouse model used in our studies is an ideal 317 model to recapitulate severe human COVID-19 pathology, high morbidity and mortality. SARS-CoV-2 318 challenge in this model leads to high viral titers in lung and brain tissues with commensurate high 319 morbidity and mortality and cytokine/chemokine production 41,50 . Therefore, this model is ideal for testing 320 SARS-CoV-2 therapeutics due to its severe disease burden, as compared to other animal models including Solutions) diluted 1:1 with 2x minimum essential media (Gibco). The cells were then incubated for three 491 days. To fix the cells, 2 mL 8% formalin was added to each well for 30 min, following removal of the 492

Avicel/formalin solution. Cells were gently washed with 1 mL tap water/well, followed by staining with 493 200 µL 1% crystal violet for 5 min. Crystal violet was removed, and the cells were washed three times 494 with 1 mL tap water/well, then dried before the viral plaques were manually counted. Cells were fed every two days and were used for experiments after they were fully confluent (4-5 days). 541

Cells were treated with compounds for three hr prior to SARS-CoV-2 infection (MOI ≈ 1) for 72 hrs and 542 then were fixed and stained for nucleocapsid and dsRNA as described in Sections 4.5 and 4.6. 543

Quantification was performed as described in Section 4.7. Imaging was performed on the EVOS M7000 544 microscope using the following channels: 357/447nm for nuclear staining (Hoechst 33342), 470/525nm 545 for dsRNA (Alexa Fluor 488), and 531/593nm for nucleocapsid (Alexa Fluor 555). Harbor, ME). Mice were intranasally inoculated with 1x10 3 PFU/animal using passage 1 of virus 555 propagated in Vero E6 cells from isolate USA-WA1/2020 (BEI resources; NR-52281). Mice were housed 556 five per cage and fed a standard chow diet. Daily treatments were administered intranasally at 7.2 mg/kg 557 using the average weights of each group separated by sex from 1) day -1 to day 6 relative to infection 558 (total of eight treatments) or 2) from day -1 to day 2 relative to infection (total of four treatments). Mice 559 were monitored and weighed daily and euthanized at predetermined criteria for humane euthanasia 560 following approved protocols, generally when weight loss reached 20% from day of challenge or mice 561 became moribund with a clinical score >3 on a 5-point scale 61 .

Mice histopathology. For histologic examination, mouse lungs and brains were collected directly after 564 euthanasia and placed in 10% formalin for >72 hrs after which tissues were embedded in paraffin. Tissue 565 sections (4 µm) were analyzed after staining with H&E and scored blinded by an anatomic pathologist. 566

For lung, scores were applied based on the percentage of each tissue type (alveolus, vessels, etc.) affected 567 using the following criteria: (0) normal; (1) <10% affected; (2) 10-25% affected; (3) 26-50% affected; 568 and (4) >50% affected. For brains, histologic scoring was assessed for perivascular inflammation using To detect viral antigen, sections were labeled with anti-SARS-CoV-2 nucleocapsid protein rabbit 576

IgG monoclonal antibody (GeneTex; GTX635679) at 1:5000 dilution and processed using a Leica Bond 577

Max automated IHC stainer. Leica Bond Polymer Refine Detection (Leica; DS9800) with DAB was used 578 as the chromogen. Image acquisition was performed using a Roche Ventana DP200 slide scanner. Digital 579 image analysis was performed using QuPath software version 0.2.3 62,63 . Tissues were annotated to 580 include all available lung tissue or all brain tissue excluding cerebellum, as cerebellar tissue was not 581 available for all mice. Following annotation, automated detection was performed using automated SLIC 582 superpixel segmentation with a DAB mean detection threshold of 0.18892. 

Infection and vaccine-induced antibody binding and neutralization of the 591

.351 SARS-CoV-2 variant

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Cell entry mechanisms of SARS-CoV-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked 596 by a Clinically Proven Protease Inhibitor

SARS-CoV-2 dependence on host pathways

A painful lesson from the COVID-19 pandemic: the need for 600 broad-spectrum, host-directed antivirals

The furin cleavage site in the 602

SARS-CoV-2 spike protein is required for transmission in ferrets

Enteroids Derived From Inflammatory Bowel Disease Patients Display 605

Dysregulated Endoplasmic Reticulum Stress Pathways, Leading to Differential Inflammatory 606 Responses and Dendritic Cell Maturation

A pneumonia outbreak associated with a new coronavirus of probable bat origin. 608

COVID-19 Dashboard by the Center for Systems Science and Engineering

Emerging sars-cov-2 variants and impact in global 612 vaccination programs against sars-cov-2/covid-19

The variant gambit: COVID-19's next move

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for 618 drug discovery and development

The race to treat COVID-19: Potential therapeutic agents for the prevention 620 and treatment of SARS-CoV-2

Remdesivir for the Treatment of Covid-19 -Final Report

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

18. STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS -Full Text View -ClinicalTrials.gov

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized 628 with Covid-19-a double-blind randomized controlled trial

Comparison of transgenic and adenovirus hACE2 mouse models for

SARS-CoV-2 infection

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting 632 the host protein eEF1A. Science (80-. )

Efficacy of GC-376 against SARS-CoV-2 virus 1 infection in the K18 hACE2 634 transgenic mouse model 2 3

Post-infection treatment with a protease inhibitor increases survival of mice 636 with a fatal SARS-CoV-2 infection

Cleavage Site in the Spike Protein 638 of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential 640 Role of Proteases beyond Furin

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related

proteases and its metabolite GBPA exerts antiviral activity

Design and synthesis of potent, selective inhibitors of matriptase

Matriptase Proteolytically Activates Influenza Virus and Promotes Multicycle 646

Replication in the Human Airway Epithelium

Modulating the selectivity of matriptase-2 inhibitors with unnatural amino 648 acids

Inhibitors of type II transmembrane serine proteases in the treatment of diseases 650 of the respiratory tract-A review of patent literature

An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and 652

Discovery of Inhibitors as Potential Treatment of COVID-19

Simultaneous Treatment 655 of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe 656

Acute Respiratory Syndrome Coronavirus Entry

Discovery and Development of TMPRSS6 Inhibitors Modulating Hepcidin 658

Levels in Human Hepatocytes

Super resolution microscopy and deep learning identify Zika virus 660 reorganization of the endoplasmic reticulum

The molecular virology of coronaviruses

Calu-3: A human 664 airway epithelial cell line that shows cAMP-dependent Cl-secretion

Co-Culture System 667 of Human Enteroids/Colonoids with Innate Immune Cells

Enteroids Derived From Inflammatory Bowel Disease Patients Display 669

Dysregulated Endoplasmic Reticulum Stress Pathways, Leading to Differential Inflammatory 670 Responses and Dendritic Cell Maturation

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in 672

SARS-CoV-2 productively infects human gut enterocytes

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung 676 inflammation and impaired function

Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory 678

Animal and translational models of SARS-CoV-2 infection and COVID-19

Airway proteases: an emerging drug target for influenza and other 682 respiratory virus infections

Evidence of SARS-CoV2 Entry Protein ACE2 in the Human Nose and 684

SARS -CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in 686 bronchial transient secretory cells

Tmprss2 Is Essential for Influenza H1N1 Virus Pathogenesis in Mice

Rational design of a new class of protease inhibitors for the potential treatment 690 of coronavirus diseases

COVID-19 preclinical models: Human angiotensin-694 converting enzyme 2 transgenic mice

Structure-based phylogeny identifies Avoralstat as a TMPRSS2 inhibitor that 696 prevents SARS-CoV-2 infection in mice

Nafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in 698 a hamster model

Variability in docking success rates due to dataset 700 preparation

SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid 702 adaptation and cytopathology

High-Content Screening of Eukaryotic Kinase Inhibitors Identify CHK2 Inhibitor 704

Human Subtilase SKI-1/S1P Is a 706

Master Regulator of the HCV Lifecycle and a Potential Host Cell Target for Developing Indirect-707

Inhibition of human matriptase by eglin 709 c variants

Probing the substrate specificities of matriptase, matriptase-711 2, hepsin and DESC1 with internally quenched fluorescent peptides

Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting 714 enzyme 2 transgenic mice

COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. 716

SLIC superpixels compared to state-of-the-art superpixel methods

QuPath: Open source software for digital pathology image analysis

A Legacy through the Prism of Relationship Chemistry

work was supported by operating grants from the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding program of the Canadian Institutes of Health Research (CIHR) [UBR 322812; VR3-172639 (RL, PLB and FJ) and OV3-170342 (FJ)]; by a Genome British Columbia / COVID-19 Rapid Response Funding Initiative

NIH training grant [T32EB023860 (AA to support DWB) and R25GM125597 (AA to support BI)

Banting and Charles Best Canada Graduate Scholarship Award

PROTEO graduate scholarship (TV); and a MITACS Inc. Accelerate fellowship COVID-19 Award

Author contributions: Conceptualization

Am = amidinyl, Ms = mesyl, kbt = ketobenzothiazol, Cm = camostat mesylate, Cha = cyclohexylalanine of colonoids subjected to the indicated treatments are shown (Hoechst in blue, nucleocapsid in red, and dsRNA in green). Scale bars 50 µm

One-way ANOVA with Bonferroni correction was used to determine significance in (A), (C), and (E)

K18-hACE2 mice were treated once daily on day -1 to day 6 relative to SARS-CoV-2 infection and surviving mice were terminated on day 14. (B) Weight change of saline control-treated mice. (C) Weight change of N-0385(OH)-treated mice. (D) Weight change of N-0385-treated mice. (E) Survival graph. (F) Representative H&E images of lung histopathology in male (top row) and female (bottom row) mice without treatment (a, b, i, j) and treated with saline, N-0385(OH), or N-0385 (c-h, k-p). Uninfected K18 mice without treatment (a, b, I, j) were normal. Mice infected with SARS-CoV-2 (c-h, k-p) frequently developed small perivascular infiltrates of inflammatory cells (arrowhead). Severe inflammatory changes including alveolar fibrin and edema (asterisk) were present only in mice treated with saline (c, d, k, l)

µm. Figure 5. N-0385 drastically reduces SARS-CoV-2 in the lungs of mice treated with N-0385 as demonstrated by immunohistochemistry. (A) K18-hACE2 mice were treated once daily on day -1 to day 6 relative to SARS-CoV-2 infection and surviving mice were terminated on day 14. (B) Graph showing number of cells/µm 2 that were positive for SARS-CoV-2 nucleocapsid by immunohistochemistry staining; reduction in positive cells was significantly greater for the N-0385 vs saline control while N-0385(OH) was not significantly different from the saline-treated group; * modified p <0.05. One-way ANOVA with a Bonferroni used to determine significance. Error bars indicate standard deviations. (C) Representative immunohistochemistry sections of SARS-CoV-2 nucleocapsid in the lungs of the SARS-CoV-2 infected male (top row) and female (bottom row) mice from Figure 3F (a, b, g, h)

D) Representative immunohistochemistry sections of the SARS-CoV-2 nucleocapsid in brains of SARS-CoV-2 infected male (top row) and female (bottom row) mice from Figure 3G (a-d, g-j)

The authors acknowledge the support of the CL-3 facility ( 

Competing Interest Statement: RL and PLB hold patent WO2012162828A1 related to peptidomimetic serine protease inhibitors. The remaining authors declare that they have no competing interests.